Work

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

Year: 2009

Type: article

Source: Journal of Pharmacology and Experimental Therapeutics

DOI: 10.1124/jpet.109.157909

Authors: John R. Atack, Dean F. Wong, Tim D. Fryer, Christine Ryan, Sandra Sanabria, Yun Zhou, Robert F. Dannals, Wai-si Eng, Raymond E. Gibson, H. Donald Burns, Jose M. Vega, Laura Vessy, Paul Scott-Stevens, John S. Beech, Jean-Claude Baron, Bindi Sohal, Michael L. Schrag, Franklin I. Aigbirhio, Ruth M. McKernan, Richard J. Hargreaves

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Johnson & Johnson (United States), MSD (UK) Limited (United Kingdom), Johns Hopkins University, University of Cambridge, Amgen (United States), GlaxoSmithKline (United Kingdom), Novartis (Switzerland), Pfizer (United States)

Language: English

Topic: Neuroscience and Neuropharmacology Research

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute for Health and Care Research

Award: NIHR Senior Investigator Award

OpenAlex ID: W2044558761

FWCI: 1.523

Cites: 40

Cited by: 37

Related to: 10